Write in a clean editor, then format for Trials in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Trials is a peer-reviewed journal published by BMC (BioMed Central), covering Ethics in Clinical Research, Meta-analysis and systematic reviews, Statistical Methods in Clinical Trials. Over its lifetime it has published 12,233 papers, which have received 221,668 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Trials. 2023;12(3):45–58.
Formats any DOI in Trials style. No sign-up. |
| Publishes research in | Ethics in Clinical Research Meta-analysis and systematic reviews Statistical Methods in Clinical Trials Health Systems, Economic Evaluations, Quality of Life Health Policy Implementation Science |
| ISSN | 1745-6215 |
| Citation impact (2-yr) | 2.08 |
| h-index | 132 |
| i10-index | 5,860 |
| Article processing charge | $1,925 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | University College London |
| Journal website | trialsjournal.biomedcentral.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: In systematic reviews and meta-analyses, time-to-event outcomes are most appropriately analysed using hazard ratios (HRs). In the absence of individual patient data (IPD), methods are available to obtain HRs and/or associated statistics by carefully manipulating published or other summary data. Awareness and adoption of these methods is somewhat limited, perhaps because they are published…
The selection of appropriate outcomes is crucial when designing clinical trials in order to compare the effects of different interventions directly. For the findings to influence policy and practice, the outcomes need to be relevant and important to key stakeholders including patients and the public, health care professionals and others making decisions about health care.…
The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience. To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also…
The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and the public,…
BACKGROUND: In cooperation with the Core Outcome Measures in Effectiveness Trials (COMET) initiative, the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) initiative aimed to develop a guideline on how to select outcome measurement instruments for outcomes (i.e., constructs or domains) included in a "Core Outcome Set" (COS). A COS is an agreed…
